Evidence map›Paper›PMID 42760579›Full record

Observational studyMalaria journal2026

Association between number of previous malaria episodes and treatment failure among children and adults with laboratory-confirmed Plasmodium infection treated with pyronaridine-artesunate in Gabon: a retrospective cohort study.

Ghyslain Mombo-Ngoma, Augusto Meneguim, Rella Zoleko Manego, Francine Ntoumi, Diane Egger-Adam, Jangsik Shin, Ayola Akim Adegnika, Sarah Arbe-Barnes, Isabelle Borghini-Fuhrer, Stephan Duparc and 4 more

Abstract readObservational Study
In one paragraph

Observational study in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ghyslain Mombo-NgomaCentre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.
Augusto MeneguimCenter for Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I Dept. of Medicine University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Rella Zoleko ManegoCentre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.
Francine NtoumiFondation Congolaise pour la Recherche Médicale (FCRM), WHO-AFRO Campus Djoué, Hospital of Talangai (North) of Brazzaville, Brazzaville, Republic of Congo.
Diane Egger-AdamInstitut für Tropenmedizin, University of Tübingen, Tübingen, Germany.
Jangsik ShinShin-Poong Pharmaceutical Co. Ltd, Seoul, Korea.
Ayola Akim AdegnikaCentre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.
Sarah Arbe-BarnesArtemida Pharma, Stevenage, UK.
Isabelle Borghini-FuhrerMedicines for Malaria Venture, Geneva, Switzerland.
Stephan DuparcMedicines for Malaria Venture, Geneva, Switzerland.
Peter G KremsnerCentre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.
Michael RamharterCentre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.
Jackie CookLondon School of Hygiene and Tropical Medicine, London, UK.
Mirjam GrogerCenter for Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I Dept. of Medicine University Medical Center Hamburg-Eppendorf, Hamburg, Germany. groger@bnitm.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalaria remains a public health challenge in Gabon. Pyronaridine-artesunate is an effective oral treatment for uncomplicated malaria. In real-world context, treatment failures, though still rare, are expected to be more frequent than in clinical trials. Prior malaria episodes have been suggested as risk factor for treatment failure. However, most evidence relies on self-reported history, which is prone to bias.

methodsA secondary data analysis of the CANTAM study, a prospective multicenter single arm open-label phase IIIB/IV study assessing the safety and efficacy of pyronaridine-artesunate in real-world context, was conducted. Adults and children weighing ≥ 5 kg with uncomplicated malaria were included. Data from the Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon, were used in this sub-group analyses to assess the impact of previous malaria episodes on the risk for treatment failure, measured both as recurrence and recrudescence. Multivariate logistic regression models were used to adjust for potential confounders.

resultsFrom June 2017 to March 2019, 2,082 patients were enrolled in Gabon; 1,969 were included in the intention-to-treat and 1,687 in the per-protocol analysis. Adults comprised 22.6% and males 53.7% of participants. In the per-protocol population, 129 (7.7%) participants experienced recurrence from which 22 (1.3%) were recrudescence. Repeated malaria episodes accounted for 294 (17.4%) of the malaria cases. Each one-year increase in age was associated with 11% decrease in the odds of recurrence (OR 0.89, 95%CI 0.86-0.92; p-value < 0.001) and recrudescence (OR 0.89, 95%CI 0.81-0.97; p-value 0.007). Previous malaria was associated with recurrence (OR 1.96; 95%CI 1.31-2.94; p-value 0.001) and recrudescence (OR 2.44; 95%CI 1.01-5.94; p-value 0.049) in the per-protocol multivariate analysis. The association between prior malaria and treatment failure was modified by age, indicating that treatment failure was less associated with previous exposure in older children.

conclusionsPrevious malaria episodes may constitute a surrogate marker for increased risk of recurrence and recrudescence, particularly in younger children. This association may reflect increased vulnerability or transient alterations in host immunity, although other unmeasured factors may also contribute. This understanding could improve malaria management in high-transmission settings, highlighting the need for targeted follow-up of patients at highest risk of treatment failure.

Indexed as

AntimalarialsArtesunateMalariaNaphthyridinesAdolescentAdultChildChild, PreschoolClinical Trials, Phase III as TopicClinical Trials, Phase IV as TopicDrug CombinationsFemaleGabonHumansInfantMaleAntimalarialsArtesunateDrug CombinationsNaphthyridinespyronaridineMalariaPlasmodium infectionPrior infectionPyronaridine-artesunateRecrudescenceRecurrenceTreatment failure

Identifiers

PMID42760579
PMCPMC13587473

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.